Treatment of chronic hepatitis B and C in children

Future Virology

Volumn 7, Issue 10, 2012, Pages 955-972

  Indolfi, Giuseppe ^a   Nesi, Alessandro ^a   Resti, Massimo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

antiviral; children; chronic viral hepatitis; hepatitis B virus; hepatitis C virus; interferon; treatment; virological response

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; AMINOTRANSFERASE; BOCEPREVIR; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYROID ANTIBODY; THYROTROPIN; UNINDEXED DRUG; VIRUS DNA; VIRUS RNA;

ABDOMINAL PAIN; ACUTE HEPATITIS; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BEHAVIOR CHANGE; BLINDNESS; CHILDHOOD DISEASE; CONSENSUS; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; GROWTH RETARDATION; HALLUCINATION; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INJECTION SITE ERYTHEMA; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDICAL DECISION MAKING; MOOD CHANGE; MOOD DISORDER; MOUTH PAIN; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RETINA EXUDATE; REVIEW; SIDE EFFECT; SORE THROAT; SUICIDE ATTEMPT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING; WEIGHT REDUCTION;

EID: 84867653394     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.94     Document Type: Review

References (73)

1. Williams R. Global challenges in liver disease. Hep a to logy 44(3), 521-526 (2006). (Pubitemid 44433707)
2. Zanetti AR, van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26(49), 6266-6273 (2008).
3. Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin. Infect. Dis. 27(1), 100-106 (1998). (Pubitemid 28334427)
4. Stadler LP, Mezoff AG, Staat MA. Hepatitis B virus screening for internationally adopted children. Pediatrics 122(6), 1223-1228 (2008).
5. Indolf G, Resti M. Perinatal transmission of hepatitis C virus infection. J. Med. Virol. 81(5), 836-843 (2009).
6. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J. Viral. Hepat. 7(2), 93-103 (2000). (Pubitemid 30177099)
7. Minola E, Baldo V, Baldovin T, Trivello R, Floreani A. Intrafamilial transmission of hepatitis C virus infection. Eur. J. Epidemiol. 21(4), 293-297 (2006). (Pubitemid 43725487)
8. Beasley RP, Hwang LY, Lee GC et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2(8359), 1099-1102 (1983). (Pubitemid 14242389)
9. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 151(4), 599-603 (1985). (Pubitemid 15102154)
10. Coursaget P, Yvonnet B, Chotard J et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J. Med. Virol. 22(1), 1-5 (1987). (Pubitemid 17077593)
11. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: fnal report of a 29-year longitudinal study. Hepatology 43 (3), 556-562 (2006).
12. Iorio R, Giannattasio A, Cirillo F, D Alessandro L, Vegnente A. Long-term out come in children with chronic hepatitis B: a 24-year observation period. Clin. Infect. Dis. 45(8), 943-949 (2007). (Pubitemid 47580340)
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57(1), 167-185 (2012).
14. Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. J. Hepatol. doi:10.1016/j. jhep.2012.03.036 (2012) (Epub ahead of print).
15. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The signifcance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 22(5), 1387-1392 (1995).
16. Arase Y, Ikeda K, Suzuki F et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am. J. Med. 119(1), 9-16 (2006).
17. Raimondo G, Allain JP, Brunetto MR et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49(4), 652-657 (2008).
18. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 49(5 Suppl.), S156-S165 (2009).
19. Bréchot C, Hadchouel M, Scotto J et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc. Natl Acad. Sci. USA 78(6), 3906-3910 (1981). (Pubitemid 11060585)
20. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically signifcant or purely 'occult'? Hepatology 34(1), 194-203 (2001). (Pubitemid 32591500)
21. Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J. Pediatr. 144(3), 397-399 (2004).
22. Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen MF. Prevalence of fbrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am. J. Gastroenterol. 103(6), 1421-1146 (2008).
23. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin. Liver Dis. 11(4), 797-816 (2007). (Pubitemid 350019025)
24. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann. Intern. Med. 147(1), 58-61 (2007).
25. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 49(5 Suppl.), S45-S55 (2009).
26. Chang MH, Chen PJ, Chen JY et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology 13(2), 316-320 (1991).
27. Yeung LT, Roberts EA. Current issues in the management of paediatric viral hepatitis. Liver Int. 30(1), 5-18 (2010).
28. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50(3), 661-662 (2009).
29. Sokal EM, Conjeevaram HS, Roberts EA et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114(5), 988-995 (1998). (Pubitemid 28217565)
30. Jonas MM, Mizerski J, Badia IB et al. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 346(22), 1706-1713 (2002). (Pubitemid 34547484)
31. Jonas MM, Kelly D, Pollack H et al. Safety, effcacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 47(6), 1863-1871 (2008). (Pubitemid 351945554)
32. Dikici B, Bosnak M, Bosnak V et al. Combination therapy for children with chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 17(10), 1087-1091 (2002). (Pubitemid 35013964)
33. Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon alpha 2a combination treatment in naive HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center's experience. Eur. J. Pediatr. 166(3), 195-199 (2007). (Pubitemid 46352505)
34. Akman SA, Okcu SC, Halicioǧlu O et al. Therapeutic effcacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr. Int. 49(6), 848-852 (2007). (Pubitemid 350197117)
35. Dantiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G. Combined lamivudine/interferon-alpha treatment in 'immunotolerant' children perinatally infected with hepatitis B: a pilot study. J. Pediatr. 148(2), 228-233 (2006).
36. Shah U, Kelly D, Chang MH et al. Management of chronic hepatitis B in children. J. Pediatr. Gastroenterol. Nutr. 48(4), 399-404 (2009).
37. Jonas MM, Block JM, Haber BA et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 52(6), 2192-2205 (2010).
38. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 41(1), 45-51 (2005).
39. Resti M, Jara P, Hierro L et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J. Med. Virol. 70(3), 373-377 (2003). (Pubitemid 36638049)
40. Bortolotti F, Verucchi G, Cammà C et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 134(7), 1900-1907 (2008). (Pubitemid 351783258)
41. Bortolotti F, Iorio R, Resti M et al. Epidemiological profle of 806 Italian children with hepatitis C virus infection over a 15-year period. J. Hepatol. 46(5), 783-790 (2007). (Pubitemid 46529042)
42. Bortolotti F, Resti M, Marcellini M et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut 54(6), 852-857 (2005). (Pubitemid 40732105)
43. Jara P, Resti M, Hierro L et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin. Infect. Dis. 36(3), 275-280 (2003). (Pubitemid 36169661)
44. Posthouwer D, Fischer K, van Erpecum KJ et al. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion 46(8), 1360-1366 (2006). (Pubitemid 44117964)
45. Mohan P, Colvin C, Glymph C et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J. Pediatr. 150(2), 168-174 (2007).
46. Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl. J. Med. 342(4), 290-291 (2000).
47. Rumbo C, Fawaz RL, Emre SH et al. Hepatitis C in children: a quaternary referral center perspective. J. Pediatr. Gastroenterol. Nutr. 43(2), 209-216 (2006). (Pubitemid 44180507)
48. Zancan L, Strafella MS, Brugiolo A et al. Chronic hepatitis C virus infection in childhood and early cirrhosis: it is possible? J. Pediatr. Gastroenterol. Nutr. 30(3), 350-351 (2000). (Pubitemid 30366849)
49. Guido M, Rugge M, Jara P et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 115(6), 1525-1529 (1998). (Pubitemid 28546004)
50. Badizadegan K, Jonas MM, Ott MJ et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 28(5), 1416-1423 (1998). (Pubitemid 28493855)
51. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin. Infect. Dis. 41(10), 1431-1437 (2005). (Pubitemid 41579984)
52. Schwarz KB, Gonzalez-Peralta RP, Murray KF et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140(2), 450-458 (2011).
53. Indolf G, Bartolini E, Olivito B, Azzari C, Resti M. Autoimmunity and extrahepatic manifestations in treatment-naive children with chronic hepatitis C virus infection. Clin. Dev. Immunol. 785627 (2012).
54. Giannattasio A, Spagnuolo MI, Sepe A et al. Is HCV infection associated with liver steatosis also in children? J. Hepatol. 45(3), 350-354 (2006). (Pubitemid 44142107)
55. Nydegger A, Srivastava A, Wake M et al. Health-related quality of life in children with hepatitis C acquired in the frst year of life. J. Gastroenterol. Hepatol. 23(2), 226-230 (2008). (Pubitemid 351257659)
56. Rodrigue JR, Balistreri W, Haber B et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J. Pediatr. Gastroenterol. Nutr. 48(3), 341-347 (2009).
57. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4), 1433-1444 (2011).
58. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 55(2), 245-264 (2011).
59. Hierro L, Alvarez L, Lledìn MD et al. IL28b gene polymorphisms in children with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 52(Suppl. 1), E22 (2011).
60. Wirth S, Pieper-Boustani H, Lang T et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41(5), 1013-1018 (2005). (Pubitemid 40593909)
61. Jara P, Hierro L, de la Vega A et al. Effcacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr. Infect. Dis. J. 27(2), 142-148 (2008).
62. Wirth S, Ribes-Koninckx C, Calzado MA et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J. Hepatol. 52(4), 501-507 (2010).
63. Sokal EM, Bourgois A, Stéphenne X et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J. Hepatol. 52(6), 827-831 (2010).
64. Al Ali J, Owayed S, Al-Qabandi W et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann. Hepatol. 9(2), 156-160 (2010).
65. Indolf G, Stagi S, Bartolini E et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin. Endocrinol. (Oxford) 6 8 (1), 117-121 (2008). (Pubitemid 350243491)
66. Jonas MM, Balistreri W, Gonzalez-Peralta RP et a l. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 56(2), 523-531 (2012).
67. Narkewicz MR, Rosenthal P, Schwarz KB et a l. ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J. Pediatr. Gastroenterol. Nutr. 51(2), 183-186 (2010).
68. Welsch C, Zeuzem S. Will interferon-free regimens prevail? Gastroenterology 142(6), 1351-1355 (2012).
69. Sokal EM, Kelly DA, Mizerski J et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 43(2), 225-232 (2006).
70. Jonas MM, Little NR, Gardner SD; International Pediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J. Viral. Hepat. 15(1), 20-27 (2008). (Pubitemid 350243578)
71. Jonas MM, Kelly D, Pollack H et al. Effcacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 31(6), 578-582 (2012).
72. Murray KF, Szenborn L, Wysocki J et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology (2012) (In Press).
73. Jacobson IM, Pawlotsky JM, Afdhal NH et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J. Viral Hepat. 19(2), 1-26 (2012).